October 14, 2021

What to Watch Out For When Investing | Midas Letter RAW ft DELC, CYBN, CLVR

Midas Letter
Midas Letter
What to Watch Out For When Investing | Midas Letter RAW ft DELC, CYBN, CLVR
/

First and foremost, Midas Letter wants to thank all of our watchers as our YouTube audience surpasses 30,000 subscribers. We wouldn’t have a show without you, and our gratification can not fully be expressed and only be shown by us continuing to do what we do. We are always trying to add value to our investor community, and today is no exception. On this week’s show and every other show from now on, we want to show you how we perform our due diligence on the stocks we trade and things to watch out for when investing.

Today’s show answers audience questions about the rising copper price, solar energy, bitcoin (BTC), psychedelic/cannabis stocks, Elon Musks’ investment into nickel, and his positive comments towards psychedelics.

We also have three exclusive CEO interviews on deck in today’s episode:

Delic Holdings Inc (CNSX:DELC, OTCMKTS:DELCF) CEO Matt Stang

Delic is the first psychedelic umbrella platform with a private equity-style model. The company owns and operates a number of businesses within the shroom boom realm. For example, Delic recently became the largest psychedelic wellness chain in the United States with its acquisition of Ketamine Infusion Centers and Ketamine Wellness Centers. They also operate Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; media and e-commerce platforms Reality Sandwich and Delic Radio; and Meet Delic, a psychedelic wellness event with hosts such as NBA star Lamar Odem.

Cybin Inc (NEO:CYBNNYSEAMERICAN:CYBN) CEO Doug Drysdale

Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin became the first NYSEAMERICAN traded psychedelics company in August and raised C$34 million in the process. The company is working on over 50 different proprietary psychedelic molecules based upon DMT, MDMA, Psilocybin, and other psychedelics. Their molecules are being studied in over 20 pre-clinical studies.

Clever Leaves Holdings Inc (NASDAQ:CLVR) CEO Kyle Detwiler

Clever Leaves is a global cannabis company with large-scale cultivation, operations and investments in the United States, Canada, Colombia, Germany and Portugal. The company achieves low-cost cannabis production by growing in Colombia and Portugal. In its latest financials, Clever Leaves reported all-in cost per gram of dry flower equivalent was $0.22. Its global cultivation footprint is a massive 1.9M sq ft, equating to half of Colombia’s national and 18% of global THC quota. The company successfully exports its medical cannabis products to over 15+ countries.

Transcript

00:00 – Midas Letter RAW
00:54 – 30K YouTube Subscribers
01:20 – Copper Price
01:58 – Voxtur Analytics
03:18 – Show Rundown
03:59 – Audience Questions
04:04 – What to watch out for when investing?
05:38 – Elon Musk’s positive psychedelic comments
05:58 – Solar energy
07:19 – Opinion on IONIC Brands (CNSX:IONC)?
13:55 – *Delic Holdings CEO Matt Stang interview*
26:58 – CNSX:DELC chart
30:37 – Bitcoin (BTC)
32:49 – *Cybin Inc CEO Doug Drysdale interview*
43:38 – NEO:CYBN chart
46:41 – Voxtur Analytics (CVE:VXTR) chart
51:46 – Copper chart
52:47 – US Copper (CVE:USCU) chart
55:18 – Elon Musk & Tesla Vale Nickel mine deal
56:12 – Nickel chart
57:26 – Canada Nickel Company (CVE:CNC) chart
58:45 – **Clever Leaves holdings CEO Kyle Detwiler interview****
1:09:24 – NASDAQ:CLVR chart

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.